Thalidomide

Dermatologic Clinics

Volumn 19, Issue 1, 2001, Pages 87-103

  Radomsky, Carrie L ^b   Levine, Norman ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; APHTHOUS STOMATITIS; APHTHOUS ULCER; BEHCET DISEASE; DRUG ABSORPTION; DRUG ELIMINATION; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HISTIOCYTOSIS X; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURIGO; PYODERMA GANGRENOSUM; REVIEW; SARCOIDOSIS; SEDATION; TOXIC EPIDERMAL NECROLYSIS;

EID: 0035162074     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70232-1     Document Type: Article

References (113)

1. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide
2. Thalidomide treatment of recurrent erythema multiforme
3. Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: Case report and review
4. Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions
5. Prurigo nodularis and photosensitivity in AIDS: Treatment with thalidomide
6. Thalidomide for systemic lupus erythermatosus
7. Effect of thalidomide on orogenital ulceration
8. Effect of thalidomide on orogenital ulceration
9. Pyoderma gangrenosum with severe pharyngeal ulceration
10. Thalidomide in dermatology: New indications for an old drug
11. Actinic prurigo (Hutchinson's summer prurigo)
12. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
13. Use of thalidomide in leprosy
14. Thalidomide is an inhibitor of angiogenesis
15. Thalidomide revisited
16. Erosive lichen planus: Dramatic response to thalidomide
17. Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers
18. Effect of thalidomide on orogenital ulceration
19. Recurrent aphthous stomatitis of the Behcet's type: Successful treatment with thalidomide
20. Pyoderma gangrenosum of the penis
21. Effect of thalidomide on the graft versus host reaction
22. Thalidomide treatment for hypertrophic lupus erythematosus
23. Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus
24. Thalidomide in hyperalgic pharyngeal ulceration of AIDS
25. Significant response of oral aphthosis to thalidomide treatment
26. Thalidomide therapy for inflammatory dermatoses
27. Crossover study of thalidomide vs. placebo in Jessner's lymphocytic infiltration of the skin
28. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: A randomized, double-blind, placebo-controlled trial
29. Behcet's disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide
30. Treatment of Behcet's disease with thalidomide
31. Chronic cutaneous lupus erythematosus: Thalidomide treatment of 11 patients
32. Thalidomide in the treatment of chronic discoid lupus erythematosus
33. Thalidomide in the treatment of erythema nodosum leprosum: With a note on selected laboratory abnormalities in erythema nodosum leprosum
34. Recalcitrant pyoderma gangrenosum: Treatment with thalidomide
35. Thalidomide for chronic graft-versus-host disease in children
36. Thalidomide treatment for chronic graft-versus-host disease
37. Chronic cutaneous lupus erythematosus treated with thalidomide
38. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients
39. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
40. Thalidomide in severe orogenital ulceration
41. Thalidomide effects in Behcet's syndrome and pustular vasculitis
42. Thalidomide in toxic epidermal necrolysis
43. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
44. Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae
45. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report
46. Editorial response: Regression of AIDS-related Kaposi's-sarcoma during therapy with thalidomide
47. Thalidomide in toxic epidermal necrolysis
48. Successful treatment of Behcet's syndrome in an African female patient with thalidomide
49. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation
50. Treatment of discoid lupus erythematosus
51. Thalidomide in the treatment of actinic prurigo
52. Thalidomide in actinic prurigo
53. Thalidomide inhibits the replication of human immunodeficiency virus type 1
54. Thalidomide in the treatment of recurrent, mecrotic, and giant mucocutaneous aphthae and aphthosis
55. Thalidomide embryopathy
56. Thalidomide for graft-versus-host: Disease
57. Thalidomide in America: A brush with tragedy
58. The immunosuppressive drug thalidiomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures
59. Recurrent giant aphthous ulcers in a child: Protracted treatment with thalidomide
60. Adult cutaneous Langerhans cell histiocytosis: Remission with thalidomide treatment
61. Thalidomide recommended for approval under tight restrictions
62. Thalidomide in diseases associated with human immunodeficiency virus infection
63. Remission of Langerhans cell histiocytosis with thalidomide treatment
64. Thalidomide for recurrent erythema multiforme
65. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation
66. Pyoderma gangrenosum associated with Behcet's syndrome - Response to thalidomide
67. Thalidomide treatment of subacute cutaneous lupus erythematosus
68. Thalidomide therapy: An open trial
69. Thalidomide and the immune system: 4. Down-regulation of the CD26 receptor, probably involved in the binding of HIV components to T cells in primates
70. New uses of thalidomide
71. Thalidomide in oral Crohn's disease refractory to conventional medical treatment
72. Thalidomide as salvage therapy for chronic graft-versus-host disease
73. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection
74. The pharmacological basis for the treatment of photodermatoses
75. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression
76. Guideline for the clinical use and dispensing of thalidomide
77. Recurrent aphthous ulcer in patients infected with human immunodeficiency virus: Successful treatment with thalidomide
78. Thalidomide in the treatment of neuro-Behcet's syndrome
79. Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis
80. Cutaneous sarcoidosis successfully treated with low doses of thalidomide
81. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children
82. Pyoderma gangrenosum associated with Behcet's disease: Treatment with thalidomide
83. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
84. Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes
85. Thalidomide for graft-versus-host: Disease after bone marrow transplantation
86. Thalidomide in the treatment of Behcet's syndrome
87. Thalidomide in the treatment of lepra reactions
88. The treatment of lepra reaction in lepromatous leprosy: Fifteen years experience with thalidomide
89. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial
90. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide
91. Thalidomide treatment of mucosal ulcerations in HIV infection
92. Proposed mechanisms of action in thalidomide embryopathy
93. The place of thalidomide in the treatment of inflammatory disease
94. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients
95. Thalidomide and its impact in dermatology
96. Thalidomide: A surprising recovery
97. Aphthous ulcers in HIV-infected patients: Treatment with thalidomide
98. Thalidomide in dermatology and leprosy
99. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide: Report of two cases and literature review
100. Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis
101. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
102. Binding of thalidomide to α-acid glycoprotein may be involved in its inhibition of tumor necrosis factor α production
103. Treatment of prurigo nodularis with thalidomide
104. Thalidomide for genital ulcer in HIV-positive woman
105. Thalidomide for the treatment of chronic graft-versus-host disease
106. Thalidomide for treatment of graft-versus-host disease
107. Thalidomide, a potent agent for the treatment of graft-versus-host disease
108. Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus
109. Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus
110. Thalidomide treatment of prurigo nodularis
111. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
112. The potential use of thalidomide in the therapy of graft-versus-host disease - A review of clinical and laboratory information
113. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody